-
Mashup Score: 42024 IASLC CT Screening Symposium | IASLC - 2 day(s) ago
The CT Screening Symposium is a 1-day, immersive, in-person event being featured at WCLC 2024 focused on lung cancer screening technologies and best practices. …
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 40Registration - WCLC 2024 - 2 day(s) ago
Get ready to dive into cutting-edge research, connect with professionals worldwide, and hear from the best in the field. WCLC 2024 promises to be a
Source: wclc2024.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
Early Registration for #WCLC24 is now open, w/an exceptional program that encapsulates the spirit of #IASLC & its members. Join the IASLC 50yr Anniversary celebrations! We look forward to welcoming you to an inspiring, educational & enjoyable program:https://t.co/Teoo6K0KxW #LCSM https://t.co/4AlvXKo8qC
-
-
Mashup Score: 14Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm? - ILCN.org (ILCN/WCLC) - 2 day(s) ago
In a recent interview, Dr. Lecia V. Sequist, a member of the team behind the Sybil AI algorithm, discusses how technology may soon be able to predict who will develop lung cancer.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11
Dr. Narjust Florez, Lung Cancer Considered Host, encourages members to participate in the first IASLC Global Membership Survey on Inclusivity. The 5-minute survey, is available in multiple languages and aims to understand the unique needs of each of our regions and those members. The data collected will be used to improve the organization’s diversity, equity, and inclusion efforts.
Source: voicesoftheiaslc.gv-one.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination - ILCN.org (ILCN/WCLC) - 3 day(s) ago
Compared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7
Dr. Jeffrey D. Bradley presented the data from the phase III study of durvalumab in combination with and following chemoradiotherapy for patients with unresectable, stage III NSCLC during the 2024 European Lung Cancer Congress.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 31KRAS in NSCLC: Beyond G12C | IASLC - 4 day(s) ago
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, focusing on non-G12C mutations. KRAS mutations …
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
KRAS mutations are common in #lungcancer, & while there are multiple approved/active KRAS inhibitors, they are specifically for the G12C mutation. @StephenVLiu discusses KRAS mutant #NSCLC w/focus on non-G12C mutations w/Dr. Veluswamy & @MarianaBrandao0: https://t.co/iI5ORV5u8l https://t.co/RPxBJbqO5a
-
-
Mashup Score: 18Individual Registration - ACLC24 - Kowloon Shangri-La - 5 day(s) ago
Industry Supporters, Faculty, and Accepted Abstract Authors will receive specific communication regarding registration procedures. Access to Online Platform with recorded scientific sessions (made available within 48 hours) Access and download of presentation slides (if permission is granted by presenters) Access and download of posters in PDF format Opportunity to connect with registered participants (online and onsite) within the Online Platform Industry Symposia, Exhibit Hall, Welcome Reception, and
Source: www.aclc2024-iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
Register Today for #ACLC24! Join us from Oct. 17-19, in the vibrant city of Hong Kong. Experience groundbreaking sessions that encompass the latest advancements in clinical research, clinical management, & multidisciplinary care for lung/thoracic cancers. https://t.co/9H7FO72YHp https://t.co/DWOF0ikOqz
-
-
Mashup Score: 18FDA Approval: Adjuvant Alectinib for Resected NSCLC | IASLC - 5 day(s) ago
In the wake of the FDA’s approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomo …
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Challenges of Systemic Therapy for Patients with EGFR-mutated Lung Cancer After Progression on Targeted Therapy - ILCN.org (ILCN/WCLC) - 5 day(s) ago
Drs. Christi M.J. Steendam and Sushil K. Badrising review studies comparing outcomes of various treatment regimens in the search for the best-performing approach.
Source: www.ilcn.orgCategories: General Medicine News, Onc News and JournalsTweet
Register Now for the 2024 CT Screening Symposium: Forefront Advances in Lung Cancer Screening! A premier event featured @ #WCLC24, taking place in San Diego, CA, Sept. 7, & dedicated to advancing knowledge/practices in #lungcancer screening. https://t.co/ExsyHGeO44 #CTSS24 #LCSM https://t.co/n4gd5ThU2x